# Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies

> **NCT00492466** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 14 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Interferon-beta-1a
- **DRUG:** methylprednisolone

## Key facts

- **NCT ID:** NCT00492466
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2008-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492466, "Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00492466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*